Novartis AG's cancer drug Afinitor replica rolex watches has been rejected for patients with kidney cancer by Britain's health costs watchdog, which says it is costly for the country's taxpayer-funded National Health Service (NHS).
The drug, known generically as everolimus, was being thought about for the second line treatment of advanced renal cell carcinoma, but the National Institute for Health & Clinical Excellence (NICE) said it did not provide benefit to patients to justify its high cost.
"We are disappointed not to be able to replica handbags recommend everolimus as a second line treatment option," NICE chief executive Andrew Dillon said in a statement. "However, they must make zhjchv0706 positive that the money available to the NHS is used to best effect, when NHS money, like the remainder of the public sector, is under considerable financial pressure."
The decision was criticised by advocacy groups, who said it was "another disappointing blow" after NICE last year rebuffed two other drugs for kidney cancer patients.
"Once again NICE has disappointed the Replica Handbags thousands of kidney cancer sufferers in the United Kingdom by not approving everolimus, a drug which gives terminal kidney cancer patients & their families some hope," said Nick Turkentine of the James Whale Fund for Kidney Cancer.
NICE has ruled that only Pfizer's cancer Record to Hard Disk 2010 drug Sutent will be reimbursed for kidney cancer patients on the NHS, with Roche's Avastin, Bayer's Nexavar & Pfizer's Torisel also rejected as not cost-effective.
